Skip to main content

Table 3 A summary of the meta-analysis for the markedly effective rate

From: Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

AADN

0.61(0.45,0.84) P = 0.96 i2 = 0%

 

0.75(0.48,1.16) P = 0.97 l2 = 0%

0.72(0.42,1.23) P = 0.82 I2 = 0%

0.56(0.26,1.17)

–

0.74(0.54,1.01) P = 0.91 I2 = 0%

0.67(0.40,1.14) P = 0.92 I2 = 0%

0.90(0.61,1.32) P = 0.71 I2 = 0%

0.93(0.46, 1.90)

0.72(0.33, 1.59)

0.81(0.54, 1.21) P = 0.79 I2 = 0%

0.61(0.30,1.26)

0.57(0.44,0.73) P = 0.19 I2 = 35.4%

–

3.89 (2.26, 6.26)

DH

–

–

–

–

1.53

(0.84,2.80)

–

–

–

–

1.73

(0.89, 3.34)

–

–

1.22

(0.69,2.16)

–

0.8 (0.29, 1.8)

0.22

(0.07,0.52)

DS

–

–

–

–

–

–

–

0.79

(0.53,1.19)

0.75

(0.41, 1.36)

–

0.64

(0.28,1.47)

–

–

2.14 (1.02, 3.99)

0.59

(0.23,1.23)

3.3

(0.91,8.58)

DSCXQ

–

–

1.70

(0.81,3.59)

–

–

–

–

–

–

–

–

–

2.22 (0.95, 4.47)

0.61

(0.22,1.35)

3.38

(0.92,8.96)

1.16

(0.37,2.82)

DZHS

–

–

–

–

0.70

(0.32,1.48)

–

–

–

0.75

(0.33,1.72)

–

 

5.36 (1.06,16.68)

1.47

(0.26,4.87)

8.32

(1.12,30.55)

2.82

(0.44,9.73)

2.82

(0.42,9.88)

DZXX

–

–

–

–

–

–

–

–

–

–

0.94 (0.57, 1.46)

0.25

(0.13,0.44)

1.41

(0.51,3.11)

0.49

(0.21,0.96)

0.48

(0.19,1.01)

0.29

(0.05,0.93)

FFDS

–

0.61(0.38, 0.98) P = 0.89 I2 = 0%

0.74(0.51,1.07)P = 0.86 I2 = 0%

0.76(0.33, 1.76)

0.54(0.34,0.86)P = 0.70 I2 = 0%

–

0.75(0.53,1.06)P = 0.98 I2 = 0%

0.81(0.50,1.31)P = 0.65 I2 = 0%

–

3.34 (1.66, 6.14)

0.91

(0.37,1.91)

5.14

(1.48,13.28)

1.75

(0.62,4)

1.75

(0.56,4.22)

1.02

(0.16,3.51)

3.76

(1.61,7.65)

HHHSS

–

–

–

1.85

(0.79, 4.29)

–

–

–

–

2.9 (1.36, 5.46)

0.79

(0.32,1.65)

4.43

(1.29,11.37)

1.52

(0.53,3.47)

1.51

(0.49,3.6)

0.89

(0.14,3.03)

3.18

(1.56,5.83)

0.97

(0.34,2.21)

SX

–

–

–

–

–

–

–

3.27 (1.86, 5.35)

0.89

(0.42,1.66)

4.96

(1.68,11.54)

1.71

(0.68,3.58)

1.68

(0.67,3.51)

1

(0.17,3.27)

3.6

(2.03,5.97)

1.09

(0.44,2.23)

1.25

(0.52,2.55)

SXT

–

1.38(0.86, 2.22) P = 0.86 I2 = 0%

1.47

(0.79, 2.78)

–

–

–

1.27 (0.53, 2.6)

0.34

(0.13,0.76)

1.78

(0.7,3.81)

0.66

(0.21,1.62)

0.66

(0.2,1.63)

0.39

(0.06,1.38)

1.39

(0.59,2.84)

0.42

(0.14,1)

0.49

(0.16,1.16)

0.41

(0.16,0.87)

XST1

0.65

(0.37, 1.15)

–

–

–

–

2.24 (1.23, 3.77)

0.61

(0.29,1.12)

3.31

(1.25,7.23)

1.17

(0.46,2.51)

1.16

(0.43,2.56)

0.68

(0.12,2.28)

2.47

(1.36,4.14)

0.74

(0.31,1.5)

0.86

(0.35,1.77)

0.71

(0.38,1.25)

1.99

(0.85,3.94)

XST2

–

–

–

–

1.64 (0.78, 3.09)

0.45

(0.18,0.96)

2.54

(0.7,6.6)

0.86

(0.29,2.01)

0.86

(0.27,2.06)

0.5

(0.08,1.73)

1.85

(0.76,3.8)

0.55

(0.19,1.25)

0.64

(0.22,1.48)

0.53

(0.22,1.07)

1.52

(0.47,3.66)

0.79

(0.31,1.68)

LI

–

–

–

2.99 (1.53, 5.34)

0.81

(0.36,1.6)

4.43

(1.57,10.1)

1.56

(0.59,3.4)

1.52

(0.59,3.24)

0.91

(0.15,3.1)

3.24

(1.85,5.34)

1

(0.37,2.17)

1.14

(0.46,2.36)

0.96

(0.45,1.82)

2.69

(1.01,5.84)

1.41

(0.65,2.69)

2.05

(0.74,4.58)

YXDM

–

1.32

(0.67,2.61)

3.3 (2, 5.14)

0.9

(0.46,1.59)

5.09

(1.64,12.18)

1.73

(0.71,3.61)

1.73

(0.64,3.79)

1.01

(0.18,3.3)

3.69

(1.97,6.31)

1.1

(0.45,2.25)

1.28

(0.53,2.61)

1.08

(0.52,1.98)

3.04

(1.12,6.65)

1.59

(0.75,2.97)

2.27

(0.91,4.75)

1.21

(0.54,2.33)

SXN

–

1.33 (0.2, 4.65)

0.36

(0.05,1.3)

1.98

(0.24,7.46)

0.69

(0.09,2.61)

0.68

(0.09,2.47)

0.41

(0.03,1.84)

1.45

(0.23,4.95)

0.44

(0.06,1.65)

0.51

(0.07,1.86)

0.43

(0.06,1.52)

1.2

(0.15,4.48)

0.63

(0.09,2.24)

0.91

(0.11,3.45)

0.45

(0.08,1.44)

0.42

(0.06,1.51)

MLN

  1. The upper right corner is the Meta-analysis results. The bottom left corner is the network Meta-analysis results. Results are the odds ratios (OR) and related 95% credibility interval (95% CI) in the row-defining treatment compared with the column -defining treatment. OR higher than 1 favor the row-defining treatment, and vice versa. Significant effects are printed in bold. AADN aspirin + anticoagulants + dehydrant + neuroprotectant, DH Danhong injection + AADN, DS Danshen injection + AADN, DSCXQ Danshenchuangxiongqin injection + AADN, DZHS Dengzhanhuasu injection + AADN, DZXX Dengzhanxixin injection + AADN, FFDS Fufangdanshen injection + AADN, HHHSS Honghuahuangsesu injection + AADN, SX Shenxiong glucose injection + AADN, SXT Shuxuetong injection + AADN, XST1 Xueshuantong injection + AADN, XST2 Xuesetong injection + AADN, LI Ligustrazine injection + AADN, YXDM Yinxingdamo injection + AADN, SXN Shuxuening injection + AADN, MLN Mailuoning injection + AAD